HELICOBACTER PYLORI INFECTIONS
Conditions
Keywords
Helicobacter pylori therapy
Brief summary
To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan
Interventions
DRUGBismuth amoxilillin potassium
vonoprazan 20mg， Twice a day amoxicillin 750mg，Four times a day tripotassium dicitrate bismuthate 300mg，Four times a day for 14 days
Sponsors
An-Nan Hospital, China Medical University
Kaohsiung Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Subjects infected with Helicobacter pylori.
Exclusion criteria
1. Those who are allergic to the drugs used in this research. 2. Those who have had stomach surgery. 3. Those with severe liver cirrhosis or uremia or malignant tumors. 4. Women who are pregnant or breastfeeding. If you have drug allergies or pregnant women or breast-feeding women during the test period, you can withdraw from the test early.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Eradicaton rate of Helicobacter pylori | 6 weeks after finishing study drugs | 13CUBT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| evaluate side effect | 2days after taking medicine | evaluate drugy side effect by Questionnaire |
Countries
Taiwan
Outcome results
None listed